Loading...
ROCO
4114
Market cap362mUSD
Jul 09, Last price  
33.35TWD
1D
-0.60%
1Q
7.75%
Jan 2017
143.79%
IPO
292.82%
Name

Synmosa Biopharma Corp

Chart & Performance

D1W1MN
ROCO:4114 chart
P/E
14.18
P/S
1.88
EPS
2.35
Div Yield, %
1.80%
Shrs. gr., 5y
2.97%
Rev. gr., 5y
15.29%
Revenues
6.19b
+11.53%
2,678,901,0003,038,286,0003,234,960,0004,386,364,0005,140,495,0005,549,549,0006,189,262,000
Net income
822m
+20.03%
47,090,000638,112,000303,860,000799,091,000594,832,000684,683,000821,849,000
CFO
412m
-47.28%
-46,115,000254,402,000454,864,000630,247,000511,929,000780,622,000411,573,000
Dividend
Jul 11, 20250.59909 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Synmosa Biopharma Corporation, established in Taipei, Taiwan, in 1980, operates as a dedicated specialty pharmaceutical enterprise. The company manages the entire lifecycle of pharmaceutical and healthcare products, from research and development to manufacturing, marketing, and distribution, primarily serving the Taiwanese market under its proprietary Synmosa brand. Its diverse product portfolio addresses key therapeutic categories, including cardiovascular health, respiratory conditions, urology, sex hormone treatments, and oncology. These offerings are available in various formats such as effervescent tablets, granules, nasal sprays, metered-dose inhalers, hormonal preparations, and other specialized forms. Beyond its proprietary products, Synmosa also extends its expertise through contract manufacturing services. The company maintains a significant international presence, exporting its goods to numerous countries including South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, Vietnam, Myanmar, Cambodia, Peru, Costa Rica, and Nicaragua.
IPO date
Sep 09, 2002
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT